Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
magazineKeep faith with Chemring’s cyber potential
Chemring (CHG) 298.3p
Loss to date: 5%
Original entry point: Buy at 314p, 5 August 2021
Despite a positive reaction to defence firm Chemring’s (CHG) latest update, the shares are a bit below the level at which we made our positive call.
The drift in the share price seems at odds with the company’s continued progress. On 2 November it announced its US based subsidiary Chemring Sensors & Electronic Systems had won a $99 million contract from the US Department of Defense.
The full rate production contract was for the Enhanced Maritime Biological Detection system – an advanced sensor system to rapidly detect, collect and identify airborne biological warfare agents.
Chemring Australia, meanwhile, also received a contract modification valued at $20 million. This was in addition to the $22 million contract that was announced on 28 September 2021 and related to the supply of MJU-68/B infrared countermeasures in support of the F-35 programme.
Looking ahead, the company said results for the year to 31 October 2021 would be in line with the board’s expectations, with adjusted operating profit expected to come in at £57.5 million.
It is Chemring’s underappreciated cyber security business which attracted us to the stock and more detail on this area of the business when full year results are announced on 14 December could give the stock a lift.
SHARES SAYS: Still a buy.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
